London-listed pharmaceutical company Shire has agreed to buy Massachusetts-based biotechnology company Dyax Corp. for up to $6.5 billion, as part of its strategy to become a leading global biotech.
from WSJ.com: US Business http://ift.tt/1MBFvEP
via IFTTT
No comments:
Post a Comment